Japan records surprise trade deficit in July as exports weaken further
SALT LAKE CITY—Aerts Austin, the Chief Financial Officer of Sera Prognostics , Inc. (NASDAQ:SERA), a company with a market capitalization of $137.45 million, executed a stock sale valued at approximately $27,090, according to a recent SEC filing. On February 12, Austin sold 5,915 shares of Class A Common Stock at an average price of $4.58 per share. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by the company's policy. The sale occurred as the stock trades near its 52-week low of $3.84, with InvestingPro data indicating oversold conditions.
Following the sale, Austin retains ownership of 277,410 shares in the company. The sale was part of a block trade, with individual transaction prices ranging from $4.14 to $5.09 per share. According to InvestingPro analysis, Sera Prognostics maintains a healthy balance sheet with more cash than debt and a strong current ratio of 2.11. Subscribers can access 8 additional key insights about SERA's financial health and market position through the comprehensive Pro Research Report.
In other recent news, Sera Prognostics, a medical laboratory services provider, has halted its planned $50 million stock offering. The company had previously filed a prospectus supplement with the intention of selling up to $50 million of its Class A common stock through TD Securities (USA) LLC, but no shares have been sold under this arrangement. The ATM Prospectus Supplement has now been terminated, though the sales agreement with TD Cowen remains in effect.
In another development, Sera Prognostics has initiated a public offering of its Class A common stock and pre-funded warrants, with the aim of expanding U.S. commercial operations, preparing for EU growth, and pursuing FDA approval for its PreTRM test. The offering is managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets.
Furthermore, the Society for Maternal Fetal Medicine (SMFM) has published an abstract with topline results from the PRIME study conducted by Sera Prognostics. The study focuses on improving neonatal outcomes through prematurity risk assessment combined with clinical interventions. The comprehensive presentation of the study's results is scheduled to be presented later this month. These are the recent developments in the company's activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.